Castle Biosciences CEO Maetzold sells $237,682 in company stock By Investing.com

Derek J. Maetzold, President and Chief Executive Officer and a Director of Castle Biosciences Inc. (), sold shares of the company’s common stock totaling $237,682 on July 27, 2026. The sales were executed at prices ranging from $23.85 to $25.11 per share. These transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Maetzold on December 3, 2025. The stock currently trades at $24.46, down significantly from its 52-week high of $44.28 but up 68% from its 52-week low of $14.59.

Mr. Maetzold directly disposed of 5,982 shares at a weighted-average price of $24.13, and an additional 232 shares at a weighted-average price of $25.06.

Indirect sales also occurred through various trusts. The Maetzold Descendants 2020 Trust sold 1,307 shares at a weighted-average price of $24.13 and 50 shares at a weighted-average price of $25.06. The Derek Maetzold 2020 Irrevocable Trust sold 1,110 shares at $24.13 and 43 shares at $25.06. Additionally, four separate Maetzold 2018 Remainder Trusts (FBO Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, and Peter Douglas Maetzold) each sold 268 shares at $24.13 and 10 shares at $25.06. The prices for the sales at the $24.13 weighted-average ranged from $23.85 to $24.62, while the sales at the $25.06 weighted-average ranged from $24.97 to $25.11.

On the same day, Mr. Maetzold also acquired 6,214 shares of common stock by exercising stock options at a price of $2.39 per share, totaling $14,851. These options were fully vested. The timing is notable as Castle Biosciences is set to report earnings tomorrow. Analysts maintain a bullish outlook with price targets ranging from $35 to $52, and InvestingPro analysis suggests the stock is currently undervalued. For deeper insights into CSTL’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Castle Biosciences Inc. reported first-quarter revenue that exceeded expectations by 10%. This financial achievement comes as the company expands its investments in sales, marketing, and new product development. Meanwhile, Castle Biosciences received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile for atopic dermatitis, which adds to the company’s growing portfolio. Additionally, the company’s DecisionDx-Melanoma i31-SLNB test demonstrated superior performance over the Melanoma Institute Australia nomogram in a multicenter study, highlighting its effectiveness in identifying sentinel lymph node positivity risks.

Castle Biosciences also achieved a milestone with its TissueCypher Barrett’s Esophagus Test surpassing 100,000 clinical orders. This test is designed to predict the progression risk of Barrett’s esophagus to more severe conditions. On a different note, the company’s chief financial officer, Frank Stokes, was honored by the Houston Business Journal as a 2026 CFO Awards honoree. Despite these positive developments, BTIG lowered its price target for Castle Biosciences to $40 from $50, while maintaining a Buy rating, citing increased operating costs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.